arrow_back Trending Legislation
Share share

Support for Rare Disease Drugs: COVID-19 Exclusivity Extension

Leo's Law aims to support pharmaceutical companies in developing drugs for rare diseases that were impacted by the COVID-19 pandemic. It extends market exclusivity periods for these drugs, which may encourage further research and development, potentially accelerating access to new therapies for patients with rare conditions.
Key points
Extends market exclusivity periods by 180 days for orphan drugs whose development was hindered by the COVID-19 pandemic.
Applies to drugs for which applications were submitted during the COVID-19 emergency period and are exclusively for rare diseases.
The goal is to incentivize companies to continue research and bring drugs to market for patients with rare conditions, who often have limited treatment options.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Leo’s Law
Print number: HR 1805
Sponsor: Rep. Gottheimer, Josh [D-NJ-5]
Process start date: 2023-03-27
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about Support for Rare Disease Drugs: COVID-19 Exclusivity Extension

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is HR 1805.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2023-03-27.

What are the main provisions?

Key points include:

  • Extends market exclusivity periods by 180 days for orphan drugs whose development was hindered by the COVID-19 pandemic.
  • Applies to drugs for which applications were submitted during the COVID-19 emergency period and are exclusively for rare diseases.
  • The goal is to incentivize companies to continue research and bring drugs to market for patients with rare conditions, who often have limited treatment options.

What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Gottheimer, Josh [D-NJ-5].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-24.

Analysis and Potential Impact of HR 1805

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Health